Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
33
Frequently Asked Questions
What is Market Cap of Lumos Pharma Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Lumos Pharma Inc market cap is $20.37M.
What is the 52-week high for Lumos Pharma Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Lumos Pharma Inc 52 week high is $4.55 as of June 07, 2024.
What is the 52-week low for Lumos Pharma Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Lumos Pharma Inc 52 week low is $2.01 as of June 07, 2024.
What is Lumos Pharma Inc stock price today?
Lumos Pharma Inc stock price today is $2.51.
What was Lumos Pharma Inc stock price yesterday?
Lumos Pharma Inc stock price yesterday was $2.35.
What is the PE ratio of Lumos Pharma Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Lumos Pharma Inc’s P/E ratio is -0.55.
What is the Price-to-Book ratio of Lumos Pharma Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Lumos Pharma Inc P/B ratio is 1.1669.
What is Lumos Pharma Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Lumos Pharma Inc's EBITDA is -0.16.
What is the 50-day moving average of Lumos Pharma Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Lumos Pharma Inc 50-day moving average is $2.66.